Phase 3 Cardiomyopathy Trial, Recruiting NCT06711185 Sponsor: University of Campinas, Brazil Condition: Cardiomyopathy
Back to Cardiomyopathy

Phase 3 Cardiomyopathy Trial, Recruiting

NCT06711185
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are female
  • People who are over 18 years old
  • People who have been diagnosed with breast cancer
  • People whose treatment plan includes chemotherapy, with a planned total dose equivalent to 240 mg/m2 of doxorubicin (a specific chemotherapy drug)

Who may not be able to join:

  • People who have a pacemaker, cardiac defibrillator, metal clips used for a brain aneurysm, cochlear implant (hearing implant), or a valve that drains fluid from the brain to the abdomen, as these can interfere with the type of scan used in this trial
  • People who are unable to undergo the required type of scan (a cardiac MRI) due to severe claustrophobia (fear of enclosed spaces)
  • People who have significant kidney problems, specifically a low kidney filtration rate below a certain threshold (confirm with trial site for exact details)
  • People who have a previous history of heart attack, heart failure, or procedures to restore blood flow to the heart (whether by surgery or a less invasive procedure)
  • People who have a previous history of significant heart valve disease
  • People who have a previous history of diseases affecting the heart muscle (cardiomyopathies)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Otavio Rizzi Coelho-Filho, MD, MPH, PhD, University of Campinas, Brazil

Phone: +55 19 3521-7755

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
University of Campinas, Brazil
Registry
ClinicalTrials.gov
Start date
30 January 2024
Est. completion
30 January 2026

Where this trial is recruiting

🇧🇷 Brazil

Primary endpoints

Change in left ventricle ejection fraction

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov